Outcomes of parenteral nutrition in patients with advanced cancer and malignant bowel obstruction.
Advanced cancer
Malignant bowel obstruction
Parenteral nutrition
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
received:
17
10
2023
accepted:
21
02
2024
medline:
5
3
2024
pubmed:
4
3
2024
entrez:
3
3
2024
Statut:
epublish
Résumé
Malignant bowel obstruction (MBO) affects 3% to 15% of all cancer patients. In patients with advanced cancer and inoperable MBO, the average survival varies between four to nine weeks. Parenteral nutrition (PN) may improve survival in specific patient populations with malignant bowel obstruction. This retrospective, single-center cohort study aimed to review individual patient outcomes on PN in the setting of advanced cancer with a diagnosis of MBO and identify clinical and laboratory markers predictive of short- and long-term survival to further highlight patients that would benefit from PN in the setting of an inoperable MBO. In a retrospective analysis of 68 patients receiving PN for inoperable MBO, the median survival was 142 (IQR: 63.3-239.5) days. Patients experienced a median number of two hospital readmissions (range: 0-10) and spent a median of 29 days (range: 0-105) in the hospital after starting PN. Eighteen (26.5%) patients developed a catheter-related bloodstream infection (CRBSI). A diagnosis of appendiceal cancer was identified as a predictive marker of improved survival (HR: 0.53, 95% CI: 0.29-0.92, p = 0.023). The use of PN in the context of end-of-life cancer care is a practice that necessitates improvement. Recognizing the outcomes and patient experiences of PN utilization is essential to physicians and patients.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant bowel obstruction (MBO) affects 3% to 15% of all cancer patients. In patients with advanced cancer and inoperable MBO, the average survival varies between four to nine weeks. Parenteral nutrition (PN) may improve survival in specific patient populations with malignant bowel obstruction.
AIMS
OBJECTIVE
This retrospective, single-center cohort study aimed to review individual patient outcomes on PN in the setting of advanced cancer with a diagnosis of MBO and identify clinical and laboratory markers predictive of short- and long-term survival to further highlight patients that would benefit from PN in the setting of an inoperable MBO.
RESULTS
RESULTS
In a retrospective analysis of 68 patients receiving PN for inoperable MBO, the median survival was 142 (IQR: 63.3-239.5) days. Patients experienced a median number of two hospital readmissions (range: 0-10) and spent a median of 29 days (range: 0-105) in the hospital after starting PN. Eighteen (26.5%) patients developed a catheter-related bloodstream infection (CRBSI). A diagnosis of appendiceal cancer was identified as a predictive marker of improved survival (HR: 0.53, 95% CI: 0.29-0.92, p = 0.023).
CONCLUSIONS
CONCLUSIONS
The use of PN in the context of end-of-life cancer care is a practice that necessitates improvement. Recognizing the outcomes and patient experiences of PN utilization is essential to physicians and patients.
Identifiants
pubmed: 38433169
doi: 10.1007/s00520-024-08403-8
pii: 10.1007/s00520-024-08403-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
206Subventions
Organisme : NIH NCI-SOAR Grant
ID : #1R25CA240134-01
Organisme : NIH NCI-SOAR Grant
ID : #1R25CA240134-01
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Tuca A et al (2012) Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res 4:159–69
doi: 10.2147/CMAR.S29297
pubmed: 22904637
pmcid: 3421464
Mercadante S et al (2007) Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manag 33(2):217–23. https://doi.org/10.1016/j.jpainsymman.2006.06.014
doi: 10.1016/j.jpainsymman.2006.06.014
Sowerbutts A, Lal S, Sremanakova J et al (2019) Palliative home parenteral nutrition in patients with ovarian cancer and malignant bowel obstruction: experiences of women and family caregivers. BMC Palliat Care 18:120
doi: 10.1186/s12904-019-0507-5
pubmed: 31884962
pmcid: 6936090
Shaw C et al (2013) Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites. Ann Surg Oncol 20(2):497–505
doi: 10.1245/s10434-012-2643-5
pubmed: 22965572
Lee YC et al (2018) Malignant bowel obstruction in advanced gynecologic cancers: an updated review from a multidisciplinary perspective. Obstet Gynecol Int 2018:1867238
doi: 10.1155/2018/1867238
pubmed: 29887891
pmcid: 5985138
Fan B-G (2007) Parenteral nutrition prolongs the survival of patients associated with malignant gastrointestinal obstruction. JPEN J Parenter Enter Nutr 31(6):508–10. https://doi.org/10.1177/0148607107031006508
doi: 10.1177/0148607107031006508
Higashi H et al (2003) Factors affecting successful palliative surgery for malignant bowel obstruction due to peritoneal dissemination from colorectal cancer. Jpn J Clin Oncol 33(7):357–9. https://doi.org/10.1093/jjco/hyg061
doi: 10.1093/jjco/hyg061
pubmed: 12949063
Cozzaglio L et al (1997) Outcome of cancer patients receiving home parenteral nutrition. Italian Society of Parenteral and Enteral Nutrition (SINPE). JPEN. J Parenter Enteral Nutr 21(6):339–42. https://doi.org/10.1177/0148607197021006339
doi: 10.1177/0148607197021006339
pubmed: 9406131
Soo I, Gramlich L (2008) Use of parenteral nutrition in patients with advanced cancer. Appl Physiol Nutr Metab = Physiologie Appliquee, Nutrition et Metabolisme 33(1):102–6. https://doi.org/10.1139/H07-152
doi: 10.1139/H07-152
pubmed: 18347659
Sowerbutts AM et al (2018) Home parenteral nutrition for people with inoperable malignant bowel obstruction. Cochrane Database Syst Rev 8(8):CD012812. https://doi.org/10.1002/14651858.CD012812.pub2
doi: 10.1002/14651858.CD012812.pub2
pubmed: 30095168
Dzierżanowski T, Sobocki J (2021) Survival of patients with multi-level malignant bowel obstruction on total parenteral nutrition at home. Nutrients 13(3):889. https://doi.org/10.3390/nu13030889
doi: 10.3390/nu13030889
pubmed: 33801869
pmcid: 8000265
Bozzetti F, Cotogni P, Lo Vullo S, Pironi L, Giardiello D, Mariani L (2015) Development and validation of a nomogram to predict survival in incurable cachectic cancer patients on home parenteral nutrition. Ann Oncol 26(11):2335–2340. https://doi.org/10.1093/annonc/mdv365
doi: 10.1093/annonc/mdv365
pubmed: 26347103
Oke S, Ismail D, Stroud M et al (2016) OC-025 application of a survival nomogram for palliative cancer patients on home parenteral nutrition: is it valid? Gut 65:A15–A16
doi: 10.1136/gutjnl-2016-312388.25
Tirumani SH, Fraser-Hill M, Auer R, Shabana W, Walsh C, Lee F, Ryan JG (2013) Mucinous neoplasms of the appendix: a current comprehensive clinicopathologic and imaging review. Cancer Imaging 13(1):14–25. https://doi.org/10.1102/1470-7330.2013.0003
doi: 10.1102/1470-7330.2013.0003
pubmed: 23439060
pmcid: 3582328
Lu P, Fields AC, Meyerhardt JA, Davids JS, Shabat G, Bleday R, Goldberg JE, Nash GM, Melnitchouk N (2019) Systemic chemotherapy and survival in patients with metastatic low-grade appendiceal mucinous adenocarcinoma. J Surg Oncol 120(3):446–451. https://doi.org/10.1002/jso.25599
doi: 10.1002/jso.25599
pubmed: 31236958
pmcid: 6675644
Kolla BC, Petersen A, Chengappa M, Gummadi T, Ganesan C, Gaertner WB, Blaes A (2020) Impact of adjuvant chemotherapy on outcomes in appendiceal cancer. Cancer Med 9(10):3400–3406. https://doi.org/10.1002/cam4.3009
doi: 10.1002/cam4.3009
pubmed: 32189461
pmcid: 7221299
Obling SR, Wilson BV, Kjeldsen J (2018) Home parenteral support in patients with incurable cancer. Patient characteristics of importance for catheter related complications and overall survival. Clin Nutr ESPEN. 28:88–95. https://doi.org/10.1016/j.clnesp.2018.09.073
doi: 10.1016/j.clnesp.2018.09.073
pubmed: 30390898
Solomon R, Egorova N, Adelson K, Smith CB, Franco R, Bickell NA (2019) Thirty-day readmissions in patients with metastatic cancer: room for improvement? J Oncol Pract 15(5):e410–e419. https://doi.org/10.1200/JOP.18.00500
doi: 10.1200/JOP.18.00500
pubmed: 30925070
Morita T, Kuriya M, Miyashita M, Sato K, Eguchi K, Akechi T (2014) Symptom burden and achievement of good death of elderly cancer patients. J Palliat Med 17(8):887–893. https://doi.org/10.1089/jpm.2013.0625
doi: 10.1089/jpm.2013.0625
pubmed: 25083586
Tal O, Ben Shem E, Peled O, Elyashiv O, Levy T (2022) Age disparities in end of life symptom management among patients with epithelial ovarian cancer. J Palliat Care 28:8258597221083418. https://doi.org/10.1177/08258597221083418
doi: 10.1177/08258597221083418
Vijayvergia N, Dotan E, Devarajan K, Hatahet K, Rahman F, Ricco J, Lewis B, Gupta S, Cohen SJ (2015) Patterns of care and outcomes of older versus younger patients with metastatic pancreatic cancer: a fox chase cancer center experience. J Geriatr Oncol 6(6):454–461. https://doi.org/10.1016/j.jgo.2015.08.001 . (ISSN 1879-4068)
doi: 10.1016/j.jgo.2015.08.001
pubmed: 26296909
pmcid: 4921214
Emiloju OE, Djibo DAM, Ford JG (2020) Association between the timing of goals-of-care discussion and hospitalization outcomes in patients with metastatic cancer. Am J Hosp Palliat Care 37(6):433–438. https://doi.org/10.1177/1049909119882891
doi: 10.1177/1049909119882891
pubmed: 31635471
Fonseca G et al (2018) The relationship between parenteral nutrition and central line-associated bloodstream infections: 2009–2014. JPEN. J Parenter Enter Nutr 42(1):171–175. https://doi.org/10.1177/0148607116688437
doi: 10.1177/0148607116688437
Elfassy S, Kassam Z, Amin F, Khan KJ, Haider S, Armstrong D (2015) Epidemiology and risk factors for bloodstream infections in a home parenteral nutrition program. J Parenter Enter Nutr 39:147–153
doi: 10.1177/0148607113502361
Huisman-de Waal G, Schoonhoven L, Jansen J, Wanten G, van Achterberg T (2007) The impact of home parenteral nutrition on daily life—a review. Clin Nutr 26(3):275–288. https://doi.org/10.1016/j.clnu.2006.10.002
doi: 10.1016/j.clnu.2006.10.002
pubmed: 17161888
Richards DM, Irving MH (1997) Assessing the quality of life of patients with intestinal failure on home parenteral nutrition. Gut 40(2):218–222
doi: 10.1136/gut.40.2.218
pubmed: 9071935
pmcid: 1027052
Baxter JP, Fayers PM, Bozzetti F, Kelly D, Joly F, Wanten G, Jonkers C, Cuerda C, van Gossum A, Klek S, Boudreault MF, Gilbert A, Jobin M, Staun M, Gillanders L, Forbes A, O’Callaghan M, Faedo CM, Brunelli C, Mariani L, Pironi L, Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of the European Society for Clinical Nutrition and Metabolism (ESPEN) (2019) An international study of the quality of life of adult patients treated with home parenteral nutrition. Clin Nutr 38(4):1788–1796. https://doi.org/10.1016/j.clnu.2018.07.024
doi: 10.1016/j.clnu.2018.07.024
pubmed: 30115461
Kirk C, Pearce MS, Mathers JC, Thompson NP, Gemmell L, Jones DE (2023) Quality of life and home parenteral nutrition: a survey of UK healthcare professionals' knowledge, practice and opinions. J Hum Nutr Diet 36(3):687–696. https://doi.org/10.1111/jhn.13103
Hoppenot C, Peters P, Cowan M, Moore ED, Hurteau J, Lee NK, Yamada SD (2019) Malignant bowel obstruction due to uterine or ovarian cancer: are there differences in outcome? Gynecol Oncol 154(1):177–182. https://doi.org/10.1016/j.ygyno.2019.04.681
doi: 10.1016/j.ygyno.2019.04.681
pubmed: 31056111